Global Reach
REGISTRAT-MAPI’s ability and experience to conduct Late Phase studies extends around the globe. We have more than two hundred employees in ten locations and have conducted studies in over 32 countries.
Our track record of success in multi-country studies enables our clients to confidently rely on us as these studies become increasingly important. Because of our singular focus on Late Phase, REGISTRAT-MAPI is a leader in addressing its unique challenges. Efficient and effective real-world research demands an intimate understanding of region, country, and local laws, regulations, and culture. We bring knowledge directly to our clients and not through a maze of other organizational focal points and priorities.
The globalization trend of the biopharma and medical device industries is indisputable. The “pharmerging” markets in Asia, South America, and elsewhere represent the greatest areas of clinical and commercial growth. With the universally growing need to assess post-approval safety, comparative effectiveness, and economic impact, multi-national biopharma is more often than ever faced with similar objectives in dissimilar environments. REGISTRAT-MAPI helps our clients confidently navigate the need to balance the myriad of challenges associated with designing and executing these studies.